Table 2.
Phase-II quantitative anticonvulsant evaluation in mice (i.p.).
| Compound | ED50 a (MES, mg/kg) | TD50 b (mg/kg) | PI c |
|---|---|---|---|
| 4e | 48.19 (33.11–70.15) d | 163.26 (142.88–186.64) | 3.4 |
| 9a | 63.31 (46.17–86.82) | >500 | >7.9 |
| 9d | 68.16 (53.74–86.44) | 378.62 (322.56–444.00) | 5.6 |
| Valproate | 272 (247–338) | 426 (369–450) | 1.6 |
| Carbamazepine | 11.8 (8.5–16.4) | 71.6 (45.9–153) | 8.1 |
a ED50: median effective dose affording anticonvulsant protection in 50% of animals, the dose is measured in mg/kg; b TD50: median toxic dose eliciting minimal neurological toxicity in 50% of animals, the dose is measured in mg/kg; c PI: protective index (TD50/ED50); d 95% confidence intervals given in parentheses.